The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2024

Filed:

Oct. 12, 2018
Applicant:

E&s Healthcare Co., Ltd., Daejeon, KR;

Inventors:

Kyong Hoon Suh, Daejeon, KR;

Dae Joong Kim, Seoul, KR;

Young Kim, Cheongju-si, KR;

Mi Kyung Kim, Daejeon, KR;

Jong Hwan Jung, Daejeon, KR;

Ki Se Lee, Sejong, KR;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/08 (2006.01); C07K 7/00 (2006.01); C07K 7/06 (2006.01); C07K 14/00 (2006.01); C07K 16/40 (2006.01); G01N 33/543 (2006.01); G01N 33/574 (2006.01); G01N 33/577 (2006.01); G01N 33/58 (2006.01);
U.S. Cl.
CPC ...
G01N 33/57415 (2013.01); C07K 7/08 (2013.01); C07K 16/40 (2013.01); G01N 33/54393 (2013.01); G01N 33/577 (2013.01); G01N 33/581 (2013.01); C07K 7/00 (2013.01); C07K 7/06 (2013.01); C07K 14/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01);
Abstract

The present invention relates to an epitope of a thioredoxin-1 (Trx1) antigen and a use thereof, and more particularly, to the epitope, and an antibody or an antigen-binding fragment binding thereto. The epitope region of the human Trx1 antigen confirmed in the present invention may be effectively used in the development of an improved antibody to enhance the binding affinity of an anti-Trx1 antibody. In addition, the improved antibody of the present invention is effective in improvement of performance of a breast cancer diagnosis kit due to excellent binding affinity for Trx1 and very high sensitivity and specificity, compared to a conventional anti-Trx1 antibody. Further, the accuracy and reliability of breast cancer diagnosis may significantly increase because exceptionally high sensitivity and specificity are exhibited by detecting the monoclonal antibody of the present invention, which specifically binds to Trx1, rather than detecting CA15-3, another conventional breast cancer diagnostic biomarker.


Find Patent Forward Citations

Loading…